Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
36858135
DOI
10.1016/j.ijpharm.2023.122784
PII: S0378-5173(23)00204-1
Knihovny.cz E-zdroje
- Klíčová slova
- Anticancer drug, Cytotoxicity, Dendrimer, Drug delivery, In vitro, In vivo, Molecular dynamics, Molecular simulations, Ruthenium, Tumor weight,
- MeSH
- komplexní sloučeniny * chemie MeSH
- lidé MeSH
- molekulární struktura MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nosiče léků MeSH
- počítačová simulace MeSH
- protinádorové látky * chemie MeSH
- ruthenium * chemie MeSH
- screeningové testy protinádorových léčiv MeSH
- triple-negativní karcinom prsu * farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- carbosilane MeSH Prohlížeč
- komplexní sloučeniny * MeSH
- nosiče léků MeSH
- protinádorové látky * MeSH
- ruthenium * MeSH
The carbosilane metallodendrimer G1-[[NCPh(o-N)Ru(η6- p-cymene)Cl]Cl]4 (CRD13), based on an arene Ru(II) complex coordinated to imino-pyridine surface groups, has been conjugated with anti-cancer drugs. Ruthenium in the positively-charged dendrimer structure allows this nanoparticle to be considered as an anticancer drug carrier, made more efficient because ruthenium has anticancer properties. The ability of CRD13 to form complexes with Doxorubicin (DOX), 5-Fluorouracil (5-Fu), and Methotrexate (MTX) has been evaluated using zeta potential measurement, transmission electron microscopy (TEM) and computer simulation. The results show that it forms stable nanocomplexes with all those drugs, enhancing their effectiveness against MDA-MB-231 cancer cells. In vivo tests indicate that the CRD13/DOX system caused a decrease of tumor weight in mice with triple negative breast cancer. However, the tumors were most visibly reduced when naked dendrimers were injected.
Citace poskytuje Crossref.org
